InnoCare Pharma Limited provided earnings guidance for the year ended December 31, 2021. For the period, the group expects to record a consolidated net loss of not more than approximately RMB 100 million as compared with a consolidated net loss of approximately RMB 464 million for the same period in 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.61 HKD | +2.44% | +0.22% | -33.09% |
May. 31 | InnoCare Pharma CEO Boosts Shareholding to 7.16% | MT |
May. 31 | InnoCare Pharma Grants Over 1.7 Million Shares Under Incentive Scheme | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.09% | 1.14B | |
+16.93% | 123B | |
+17.01% | 111B | |
-7.23% | 23.63B | |
+3.09% | 22.58B | |
-14.71% | 17.26B | |
-6.79% | 17.6B | |
-37.63% | 17.61B | |
+2.17% | 13.55B | |
+24.42% | 11.34B |
- Stock Market
- Equities
- 9969 Stock
- News InnoCare Pharma Limited
- InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended December 31, 2021